Literature DB >> 28471948

The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development.

Janessa M Smith1, Charles Flexner.   

Abstract

: It is estimated that by 2030 nearly three-quarters of persons living with HIV will be 50 years and older. The aging HIV population presents a new clinical concern for HIV providers: adverse effects from polypharmacy. An aging population means more comorbidities and potentially more drug-drug interactions for providers to manage. This review discusses major comorbidities including cardiovascular disease, anticoagulation, hypertension, diabetes mellitus and malignancy and considerations for drug-interactions with antiretrovirals.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28471948     DOI： 10.1097/QAD.0000000000001401

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  8 in total

1.  Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis.

Authors:  Amanda M Kong; Alexis Pozen; Kathryn Anastos; Elizabeth A Kelvin; Denis Nash
Journal:  AIDS Patient Care STDS       Date:  2019-03       Impact factor: 5.078

Review 2.  HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers.

Authors:  Kaku So-Armah; Matthew S Freiberg
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

3.  Reciprocal Modulation of Antiretroviral Drug and Steroid Receptor Function In Vitro.

Authors:  Sigcinile Dlamini; Michael Kuipa; Kim Enfield; Salndave Skosana; John G Woodland; Johnson Mosoko Moliki; Alexis J Bick; Zephne van der Spuy; Michelle F Maritz; Chanel Avenant; Janet P Hapgood
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

4.  Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy.

Authors:  Krista J Siefried; Limin Mao; Lucette A Cysique; John Rule; Michelle L Giles; Don E Smith; James McMahon; Tim R Read; Catriona Ooi; Ban K Tee; Mark Bloch; John de Wit; Andrew Carr
Journal:  AIDS       Date:  2018-01-02       Impact factor: 4.177

5.  Comparative study of antiretroviral drug regimens and drug-drug interactions between younger and older HIV-infected patients at a tertiary care teaching hospital in South Korea.

Authors:  Mi Seon Park; Young-Mo Yang; Ju-Sin Kim; Eun Joo Choi
Journal:  Ther Clin Risk Manag       Date:  2018-11-12       Impact factor: 2.423

6.  Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging.

Authors:  Erin E Sundermann; Kristine M Erlandson; Caitlin N Pope; Anna Rubtsova; Jessica Montoya; Alison A Moore; Catia Marzolini; Kelly K O'Brien; Savita Pahwa; Brendan A I Payne; Leah H Rubin; Sharon Walmsley; Norman J Haughey; Monty Montano; Maile Y Karris; Joseph B Margolick; David J Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2019-09-10       Impact factor: 1.723

7.  The Challenge of Potential Drug-Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China.

Authors:  Huan Xia; Liying Gao; Xiaowen Gong; Silvere D Zaongo; Tong Zhang; Hao Wu; Ping Ma; Xiaojie Huang
Journal:  Front Pharmacol       Date:  2020-05-27       Impact factor: 5.810

8.  Determination of a cutoff value for medication regimen complexity index to predict polypharmacy in HIV+ older patient.

Authors:  R Morillo-Verdugo; M A Robustillo-Cortés; L Abdel-Kader Martín; M Álvarez de Sotomayor Paz; F Lozano de León Naranjo; C V Almeida González
Journal:  Rev Esp Quimioter       Date:  2019-09-17       Impact factor: 1.553
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.